Omicia Executive Leadership

Matt Tindall, Omicia CEO

Matt Tindall

Chief Executive Officer

Matt Tindall has more than two decades of healthcare experience spanning general management, corporate development, strategy consulting, digital marketing and commercial operations. Prior to Omicia, he served as the general manager of the Consumer Solutions division of IMS Health, a leading global information and technology services company in the healthcare industry.
Show More…

During his tenure at IMS Health, Matt built an industry-leading SaaS business in the digital health space, authored multiple new intellectual property filings, led the acquisition and integration of a global technology company and assisted in the company’s transition to a become a public company (NYSE: IMS Health).

Prior to IMS Health, Matt was VP Marketing at Digitas Health New York (a subsidiary of Publicis Groupe) leading commercial marketing activities for Pfizer, BMS and Boehringer Ingelheim, worked in strategic business development for Celera Genomics, led a cardiovascular business development team focused on the development of novel gene therapy, cell therapy and biomaterial products at Genzyme Corporation and co-founded and managed a start-up biopharmaceutical company named Sarentis Therapeutics. Matt received his B.S. in Human Physiology from Lyman Brigg’s College at Michigan State University and his M.B.A. from the University of Texas at Austin.

Martin G. Reese, Ph.D.

Martin G. Reese, Ph.D.

Co-Founder, President,
and Chief Scientific Officer

Dr. Martin Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Omicia, Martin served as Vice President of Discovery Informatics for ValiGen.
Show More…

Prior to this, he co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Martin developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career he has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Martin developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and the University of California, Berkeley.
Edward S. Kiruluta

Edward S. Kiruluta

Co-Founder and
Chief Technology Officer

Edward Kiruluta is responsible for product development, operations, and IT at Omicia. Previously Edward was the Vice President of Development at Symyx Technologies, Inc., where he was responsible for the development of Symyx Notebook.
Show More…

From 2005-2008 Edward was the Vice President of Engineering at DemandTec where he led the Econometrics, Operations Research, and Database teams and saw the company through a successful IPO. Prior to this he was Senior Director of Informatics at Merck Research Labs (where he led the development of the Target Genome Index), and Chief Technology Officer at DoubleTwist, where his team developed Prophecy, the first comprehensive annotation of the human genome, and DoubleTwist.com, the first web portal for life science researchers. Edward studied Electrical Engineering at Memorial University in Canada.
Paul Billings, M.D., Ph.D.

Paul Billings, M.D., Ph.D.

Co-Founder and
Chief Medical Officer

Dr. Paul Billings serves as Chief Medical Officer at Omicia. Prior to joining Omicia, Dr. Billings was CMO at Life Technologies, acquired by Thermo Fisher Scientific, Inc. (NYSE: TMO). Before that he was founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital. Dr. Billings served as President, CEO and Director of CELLective Dx Corporation.

Show More…

Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. He was Deputy Chief of Staff and Chief of General Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. He has been Professor of Anthropology (adjunct) at UC Berkeley and has published extensively on topics in immunology, genetics and medicine. Dr. Billings received an A.B. summa cum laude from UC San Diego, and both his M.D. and Ph.D. degrees from Harvard University.
Adam Grant

Adam Grant

Chief Operating Officer

Adam Grant leads all post-sales teams and operations at Omicia, including implementation, account management, customer service, CRM, reporting, and other systems and tools. He is responsible for scaling teams, processes, and systems to retain, engage, and drive revenue from new and existing customers. Prior to Omicia, Adam held executive roles at PokitDok and Practice Fusion.
Show More…

Adam is an award-winning Operations and Customer Success executive. He has 18 years experience in healthcare and technology, with a focus on scaling SaaS business operations. Prior to Omicia, Adam was Senior Vice President of Customer Success at PokitDok, where he was responsible for all customer-facing activities and operations. Prior to PokitDok, Adam was Associate Vice President of Customer Engagement at Practice Fusion, where he led sales, implementation, account management, and service of the company’s Electronic Health Record software, and built the largest ambulatory EHR community of doctors in the US. Adam holds a B.A. in Economics from Dartmouth College and an M.S. in Organizational Behavior from Stanford University School of Engineering.
Charlene Son Rigby

Charlene Son Rigby

Vice President, Products & Strategy

Charlene Son Rigby is responsible for product management and marketing at Omicia. Charlene has spent her career building businesses at the intersection of data, technology and life sciences. Previous to Omicia, she was responsible for all go-to-market activities at Metamarkets, a big data analytics startup.
Show More…

Prior to Metamarkets, Charlene was Vice President of Business Planning at Oracle where she rolled out Analytics for the sales organization, and Executive Director of Sales Operations at Siebel Systems, a $2B license business. She also led product management at DoubleTwist, a bioinformatics startup. Charlene started her career as a neuroscience researcher at Syntex (acquired by Roche). She holds a B.A. in Human Biology from Stanford University and an M.B.A. from the Haas School of Business at U.C. Berkeley.
Mathias Klozenbuecher

Mathias Klozenbuecher

Vice President, Business Development

Mathias Klozenbuecher is responsible for all Business Development activities at Omicia. His responsibilities include 3rd party partnerships, strategic alliances, licensing and co-development opportunities.

Show More…

Prior to joining Omicia Mathias was the Head of Strategy, Business Development and Strategic Procurement for the Siemens Healthcare Molecular Diagnostics Business. In this role Mathias led all M&A activities, defined and implemented a short term revenue growth- and long term technology based business unit strategy and led all strategic procurement activities. Before that Mathias held several leadership positions within Siemens Healthcare including Marketing where he increased his products’ market share in the double digits within 12 months, Project Management where he executed a savings program bringing in over $150M in efficiencies per year, and being a member of the Diagnostics Executive Leadership Team, a $5B part of Siemens Healthcare. Mathias holds a B.A. and a M.S. in Genetics and Microbiology from the University of Vienna, Austria and from UCLA.

BOARD

In addition to Matt Tindall and Martin Reese, Omicia’s board members are:

John Stuelpnagel, D.V.M.

John Stuelpnagel, D.V.M.

Co-founder, Chairman of the Board of Directors

Dr. John Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function.
Show More…

John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008.

Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.

mike

Mike A. Aicher

Board of Directors

Mike co-founded and served as National Genetics Institute’s (NGI) CEO since 1991. NGI became a wholly owned subsidiary of Laboratory Corporation of America (NASDAQ: LH) in 2000, where he held various positions.

Show More…

He ran the company’s “Esoteric Business Units”, which generated over $1 billion in annual revenue. Mike holds a Bachelor of Science in Business Administration from the University of Redlands, a Master of Business Administration in Economics from Columbus University and is a certified Global Biotechnology Executive from the University of California, Berkeley. He also received Ernst and Young’s “Entrepreneur of the Year” award for emerging technologies.
Tad Buchanan

Tad Buchanan

Board of Directors

Mr. Buchanan co-founded the investment firm of Buchanan Investments, Inc. in 1998 with his father, Mike. Together, they have founded, invested in and raised equity and debt capital for numerous companies, including DM&E Railroad, Central Montana Resources, Opti Canada, White Oak Resources, AlphaClone, TabletCommand, Gensys Software, Tri Alpha Energy, OneSun Solar, and numerous other private companies.
Show More…

Prior to founding Buchanan Investments, Inc., Tad was an Executive Director at UBS Securities with primary responsibility for managing Asian equity sales and trading based in NY. He was also an equity analyst at UBS and W.I. Carr (Far East), Ltd. based in Hong Kong, with responsibility for covering financial services, software, industrial and energy companies in Indonesia, Thailand, India, Pakistan, Sri Lanka and Bangladesh. Prior to joining W.I. Carr (Far East) Ltd., Tad was a credit analyst within the Corporate Lending Group of Wells Fargo Bank. He graduated from Pepperdine University with a B.A. in Economics and from Boston College with an M.B.A, International Finance. He currently serves on the boards of Central Montana Resources, AlphaClone, Tablet Command, and OneSun Solar. Tad is also a board observer of Tri Alpha Energy. He is married with three children, and is a Trustee of Marin Country Day School in Corte Madera, CA.

Matt Posard

Matt Posard

Board of Directors

Matt Posard has over 25 years of general management and commercial experience in the life sciences, molecular diagnostics and genomics industry. Mr. Posard held influential leadership roles with market leading companies including Illumina, Trovagene, Biosite / Alere, and Gen-Probe.
Show More…

Mr. Posard has a distinguished reputation in commercializing transformative novel products and technology in the genomics space. Mr. Posard holds a B.A. degree in Quantitative Economics and Decision Science from the University of California, San Diego and currently serves as a board member for Halozyme Therapeutics, SlipChip Corporation, Dermtech Inc., and Envision Genomics.